Grünenthal v. Teva: NUCYNTA® ER Patent Action Dismissed Without Prejudice
Grünenthal GmbH filed suit against Teva Pharmaceutical Industries in the District of New Jersey asserting US11344512B2 covering NUCYNTA® ER tapentadol hydrochloride extended-release pain medication across five dosage strengths. The parties jointly stipulated to dismissal without prejudice under Rule 41(a)(1)(A)(ii) after 193 days, each bearing their own costs — leaving open the possibility of future re-filing.
NUCYNTA® ER ANDA dispute ends in no-merits dismissal
On May 13, 2024, Grünenthal GmbH filed a patent infringement action in the United States District Court for the District of New Jersey against Teva Pharmaceutical Industries, Ltd., asserting US11344512B2 in connection with NUCYNTA® ER (tapentadol hydrochloride), an extended-release opioid analgesic available in 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg dosage strengths. The case is consistent with standard Hatch-Waxman ANDA litigation mechanics, where a branded pharmaceutical company seeks to prevent generic entry.
On November 22, 2024, the parties filed a joint stipulation of dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all remaining claims and counterclaims without prejudice. Each party agreed to bear its own costs and attorneys’ fees. Critically, the court retained exclusive jurisdiction to adjudicate any issues arising from the resolution of this action — a clause that typically signals a structured resolution or ongoing compliance obligations.
The 193-day duration from filing to closure is notably brief for pharmaceutical patent litigation, which ordinarily spans multiple years through discovery and trial. The without-prejudice designation means Grünenthal retains the right to re-assert US11344512B2 against Teva in future proceedings. The public record does not confirm whether the dismissal reflects a settlement, a licensing arrangement, or a strategic withdrawal, and the underlying commercial terms — if any — are not publicly disclosed.
Filing to Dismissed without Prejudice in 193 days
193 days — resolved before discovery closed, suggesting early resolution pressure
Stipulated dismissal without prejudice: what the ruling means for both parties
Rule 41(a)(1)(A)(ii) dismissal — no merits ruling entered
A stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) requires agreement from all parties who have appeared and allows the case to be closed without any court adjudication of the underlying patent claims. No finding of infringement, validity, or enforceability was made. The court retains jurisdiction for any post-dismissal compliance issues, suggesting the parties may have reached a collateral arrangement not reflected in the public docket.
No merits adjudicationWithout prejudice: the distinction matters significantly
A dismissal ‘without prejudice’ preserves Grünenthal’s right to re-file claims under US11344512B2 against Teva in a future action. This contrasts with a ‘with prejudice’ dismissal, which would bar re-litigation of the same claims under res judicata principles. The public record here confirms the dismissal is without prejudice, meaning the patent infringement dispute is suspended — not resolved — from a legal standpoint. Commercial terms, if any, remain undisclosed.
Re-filing right preservedGrünenthal retains patent and litigation optionality
Grünenthal exits the litigation with US11344512B2 intact and unchallenged on the merits. No adverse validity finding was entered. The retained court jurisdiction clause is notable — it suggests Grünenthal may have secured terms that require ongoing compliance from Teva, potentially restricting generic market entry for a defined period, though this cannot be confirmed from the public record.
Patent validity preservedTeva avoids an adverse ruling but gains no clearance
Teva obtains no declaratory judgment of non-infringement or invalidity of US11344512B2. Without a court finding in its favour, Teva cannot rely on this proceeding to support a freedom-to-operate position for its tapentadol ER products. The without-prejudice dismissal means Teva faces continued exposure to re-filed infringement claims if any agreed conditions — such as a launch date or licensing threshold — are not met.
No FTO clearance obtainedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Grunenenthal GmbH | Company | German specialty pharmaceutical company — holder of US11344512B2 covering NUCYNTA® ERSearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic pharmaceutical manufacturer seeking to commercialise tapentadol ER formulationsSearch in Eureka ↗ |
| Co-Defendant | Teva Pharmaceutical Industries Limited | Company | Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Grunenenthal GmbHSearch in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Grunenenthal GmbHSearch in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Grunenenthal GmbHSearch in Eureka ↗ |
| Defendant counsel | Christine Intromasso Gannon | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Liza M. Walsh | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation language is precise: all ‘remaining claims and counterclaims’ are dismissed, indicating the parties resolved or withdrew every pleaded cause of action and defensive counterclaim — likely including any invalidity or non-infringement counterclaims Teva had filed. The phrase ‘resolution of this action’ in the retained-jurisdiction clause is deliberately broad, consistent with an underlying settlement agreement whose terms are not entered on the public docket. No merits findings were made and neither party obtained a judgment it could cite as precedent.
US11344512B2 — tapentadol hydrochloride extended-release formulation
US11344512B2, filed under application number US16/439135, covers formulation and/or method claims relating to tapentadol hydrochloride in an extended-release oral dosage form — the active ingredient in NUCYNTA® ER. Tapentadol is a centrally-acting opioid analgesic with a dual mechanism of action (mu-opioid receptor agonism and norepinephrine reuptake inhibition). Extended-release formulations in this class involve complex matrix or coating technologies that control drug-release kinetics, making them meaningful targets for patent protection well beyond the compound itself.
For generic pharmaceutical companies, the assertion of a formulation or method-of-use patent like US11344512B2 in Hatch-Waxman litigation triggers a 30-month stay on FDA ANDA approval upon timely filing. This creates substantial commercial leverage for the branded holder even before a merits ruling. With NUCYNTA® ER prescribed across a broad dosage range, patent coverage extending to all five strengths (50–250 mg) suggests Grünenthal has structured its protection to capture the full generic substitution landscape. Any company developing a tapentadol ER generic should conduct a full claim-chart analysis against this patent.
Should you run an FTO analysis against US11344512B2?
Any pharmaceutical company with an active or planned ANDA covering tapentadol hydrochloride extended-release tablets should treat US11344512B2 as a primary clearance target. The fact that Grünenthal has actively enforced this patent in federal court — and that the case closed without any validity or non-infringement finding — means the patent’s enforceability is legally intact. This applies across all five dosage strengths covered by NUCYNTA® ER; partial dosage portfolios do not automatically avoid exposure.
PatSnap Eureka’s FTO Search Agent can map the claims of US11344512B2 against your product specifications, identify relevant prior art that could support invalidity arguments, and surface related Grünenthal patent family members that may present additional clearance requirements. For formulation patents in the extended-release opioid class, family-level analysis — not single-patent review — is the appropriate standard of due diligence.
Run a freedom-to-operate analysis on US11344512B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: tapentadol ER and extended-release opioid formulations
Explore related Hatch-Waxman infringement actions involving extended-release opioid analgesic formulation patents litigated in the District of New Jersey and comparable federal venues.
What this case signals for the extended-release opioid analgesic IP landscape
Early dismissal in Hatch-Waxman cases rarely means the dispute is over — it often signals negotiated entry or deferred enforcement.
Without-prejudice dismissals in ANDA cases often precede negotiated launch dates
In Hatch-Waxman litigation, parties frequently resolve disputes through consent decrees or licensing agreements that include agreed-upon generic entry dates. A without-prejudice dismissal with retained court jurisdiction — as seen here — is structurally consistent with that outcome. Competitors and product teams in the tapentadol ER space should monitor Teva’s ANDA approval status and any generic launch activity.
US11344512B2 remains a live enforcement risk for other tapentadol ER ANDA filers
The dismissal does not limit Grünenthal’s ability to assert US11344512B2 against other generic applicants seeking to market tapentadol hydrochloride extended-release products. Companies with pending ANDAs covering NUCYNTA® ER formulations across the full dosage range should treat this patent as fully enforceable and conduct updated freedom-to-operate analysis accordingly.
Grunenenthal v Teva — key questions answered
The case was dismissed without prejudice on November 22, 2024, by joint stipulation under Rule 41(a)(1)(A)(ii). All claims and counterclaims were dismissed with each party bearing its own costs. No merits ruling on infringement or validity of US11344512B2 was entered. The court retained jurisdiction over the parties for purposes of enforcing any resolution terms.
Grünenthal asserted US11344512B2, filed under application US16/439135, covering NUCYNTA® ER (tapentadol hydrochloride) extended-release formulations in 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg dosage strengths. The patent relates to extended-release tapentadol formulation technology used in this branded opioid analgesic product.
A without-prejudice dismissal means the patent holder — here Grünenthal — retains the right to re-file infringement claims under the same patent against the same defendant in a future action. No res judicata bar applies. In Hatch-Waxman litigation, this outcome is often associated with a negotiated generic entry date or licensing arrangement, though the commercial terms are typically not disclosed in the public court record.
Courts retain jurisdiction post-dismissal when the parties have entered into a settlement or consent agreement that may require future judicial enforcement. The stipulation in this case states the court retains ‘exclusive jurisdiction over the Parties for the purpose of adjudicating any issues arising from the resolution of this action’ — language consistent with a binding side agreement governing Teva’s generic launch rights or other compliance obligations, though the specific terms are not publicly available.
No. The dismissal resolves only the dispute between Grünenthal and Teva and has no binding effect on other ANDA applicants. US11344512B2 remains in force and Grünenthal retains full enforcement rights against any third party. Other companies with pending ANDAs for tapentadol hydrochloride extended-release products should treat this patent as fully enforceable and conduct independent freedom-to-operate and invalidity analyses.
PatSnap Eureka searches patents and litigation data to answer instantly.